White label ELPA - ClinicalTrials.eu

Study Comparing Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil to Standard Treatment for Patients with Advanced Anal Cancer

Not recruiting

3 1 1 1
Investigated Diseases:
- Anal squamous cell carcinoma
Investigated Drugs:
Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Not recruiting

3 1 1
Investigated Drugs:
+10
Study of LY3540378 for Adults with Worsening Chronic Heart Failure with Preserved Ejection Fraction

Not recruiting

2 1
Investigated Drugs:
- Igg Against Serum Albumin Fused With Relaxin 2, Chain B (2-29) And Relaxin 2 (Chain A)
Study on Giredestrant and Fulvestrant with CDK4/6 Inhibitor for Patients with ER+ HER2-Negative Advanced Breast Cancer Resistant to Endocrine Therapy

Not recruiting

3 1 1 1
Investigated Drugs:
+7
Study on Patient Preference for Nivolumab and Relatlimab Administration Methods in Melanoma Patients

Not recruiting

2 1 1 1
Investigated Drugs:
- Relatlimab
- Nivolumab
Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Not recruiting

2 1 1 1
Investigated Diseases:
- Non-small cell lung cancer
Investigated Drugs:
Study of BMS-986288 and Nivolumab for Patients with Advanced Solid Tumors

Not recruiting

2 1 1 1
Investigated Diseases:
- Neoplasm
Investigated Drugs:
Study Comparing SB27 and Pembrolizumab for Patients with Metastatic Non-Small Cell Lung Cancer

Not recruiting

3 1 1 1
Investigated Diseases:
- Non-small cell lung cancer
Investigated Drugs:
Study on the Effects of Telmisartan, Amlodipine, and Hydrochlorothiazide on Blood Pressure in Patients with Hypertension

Not recruiting

3 1 1 1
Investigated Diseases:
- Hypertension
Investigated Drugs:
Study on the Effects of AZD0780 on Cholesterol Levels in Adults Aged 18-75 with Dyslipidemia

Not recruiting

2 1
Investigated Diseases:
- Dyslipidaemia
Investigated Drugs:
- 1-[6-[[(1S,3S)-3-[[5-(Difluoromethoxy)Pyrimidin-2-Yl]Amino]Cyclopentyl]Amino]Pyridin-3-Yl]Pyridin-2-One

Full Name *

e-Mail *

Country Prefix *

Phone Number *

Nationality *

Gender *

Check all consents

Check all consents

I accept the Terms and Conditions and Privacy Policy *

*I accept the Terms and Conditions and Privacy Policy

I consent to receiving commercial information from the Service Operator *

*I consent to receiving commercial information from the Service Operator

I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes *

*I consent to the use of telecommunications terminal equipment and automated calling systems by the Service Operator for marketing communication purposes

We use cookies